Stocks Health care AVLN
NASDAQ · Health careAvalyn Pharma Inc. (AVLN)
At June 30, 2026 it held $264.2M in cash against $14.8M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Avalyn Pharma Inc.
- Net worth
- Avalyn Pharma Inc. has a market value (market cap) of $1.4B at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Avalyn Pharma Inc. does
Avalyn Pharma Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AVLN.
Earnings: every quarter and the next report date
Latest SEC filings
What Avalyn Pharma Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 16, 2026Executive or director change8-KAvalyn Pharma appointed Dr. Robert Meyer to its board of directors as an independent Class II director.
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 12, 2026
- August 12, 2026
- August 11, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- July 1, 2026
- June 17, 2026
- June 3, 2026
- June 3, 2026
Insider trades
What the people running Avalyn Pharma Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 1, 2026 | Fmr LLC10% owner | Exercised optionsindirect | 727,585 | - |
| May 1, 2026 | Fmr LLC10% owner | Exercised optionsindirect | 80,291 | - |
| May 1, 2026 | Fmr LLC10% owner | Exercised optionsindirect | 872,868 | - |
| May 1, 2026 | Fmr LLC10% owner | Exercised optionsindirect | 225,843 | - |
| May 1, 2026 | Fmr LLC10% owner | Exercised optionsindirect | 377,948 | - |
| May 1, 2026 | Novo Holdings A/S10% owner | Exercised options | 3,327,734 | - |
| May 1, 2026 | Novo Holdings A/S10% owner | Bought | 555,555 | $10M |
| May 1, 2026 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P.10% owner | Exercised options | 1,275,486 | - |
Who owns AVLN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 13.2% | August 6, 2026 |
| Novo Holdings A/S13G, passive | 8.8% | August 14, 2026 |
| SR One Capital Management, LLC13D, may seek influence with 5 related filers | 7.5% | May 8, 2026 |
| Perceptive Advisors LLC13G, passive with 3 related filers | 6% | May 7, 2026 |
| Suvretta Capital Management, LLC13D, may seek influence with 3 related filers | 5.6% | May 8, 2026 |
| Norwest Venture Partners XV, LP13G, passive with 4 related filers | 5.1% | August 11, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 92 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 5,835,259 | new |
| Novo Holdings A/S | 3,883,289 | new |
| SR One Capital Management, LP | 3,308,649 | new |
| Perceptive Advisors LLC | 2,675,296 | new |
| Montanova Capital, LLC | 2,503,109 | new |
| Nvp Associates, LLC | 2,268,404 | new |
| Wellington Management Group Llp | 2,201,986 | new |
| Catalio Capital Management, LP | 1,675,830 | new |
| Eventide Asset Management, LLC | 1,375,486 | new |
| Bellevue Group AG | 1,350,000 | new |
| BlackRock, Inc. | 977,264 | new |
| Pivotal bioVenture Partners Investment Advisor LLC | 966,792 | new |
| Citadel Advisors LLC | 959,098 | new |
| Andera Partners | 929,824 | new |
| Jennison Associates LLC | 812,749 | new |
| Braidwell LP | 801,395 | new |
| Tpg GP A, LLC | 773,069 | new |
| Vanguard Capital Management LLC | 739,770 | new |
| Deerfield Management Company, L.P. | 731,000 | new |
| Rock Springs Capital Management LP | 662,918 | new |
Insiders
5 insiders reported holding 10,751,959 shares in total, about $328.4M at the last price.
| Holder | Shares |
|---|---|
| Novo Holdings A/S10% owner | 3,883,289 |
| Fmr LLC10% owner | 2,284,5352,284,535 held indirectly |
| Carroll JillDirector | 2,186,5622,186,562 held indirectly |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P.10% owner | 1,275,486 |
| Sr One Capital Management, LLC10% owner | 1,122,0871,122,087 held indirectly |
Questions about AVLN
What does Avalyn Pharma Inc. do?
Avalyn Pharma Inc. is a company in the Health care sector, listed on NASDAQ as AVLN. Its shares trade on NASDAQ under the ticker AVLN.
What is Avalyn Pharma Inc.'s net worth?
Avalyn Pharma Inc. has a market value (market cap) of $1.4B at the latest share price. A company's "net worth" usually means this market value or the shareholders' equity on its balance sheet.
When did Avalyn Pharma Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 17, 2026.
Similar companies
Compare AVLN with
Follow AVLN
Get an email when Avalyn Pharma Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Avalyn Pharma Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.